Zymeworks price to sales ratio ZYME

Market value divided by revenue over the last twelve months, since 2023.

Today, Oct 23, 2026: 53.9×
3-year median: 12.5×
Against its 3-year history: 98th; percentile: 0 is its lowest day, 100 its highest
3-year range: 1.0× to 55.8×
Peer median: 1.8×

Zymeworks' price to sales ratio is 53.9× as of Oct 23, 2026.

That is above its 3-year median of 12.5×, higher than on 98% of days in the last 3 years.

Over that time it ranged from 1.0× in Sep 2023 to 55.8× in Sep 2026.

The median for 10 large drugmakers of a similar size is 1.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	53.9×	12.5×	55.8×
2025	15.0×	7.4×	16.6×
2024	16.1×	1.5×	18.4×
2023	1.6×	1.0×	1.6×

Against its peers

Companies in Drug Manufacturers - General nearest Zymeworks' size, closest first, today.

Company	Price to sales ratio
ZYMEZymeworks	53.9×
HRMYHarmony Biosciences	2.2×
PBHPrestige Consumer Healthcare	2.0×
ANIPANI Pharmaceuticals	1.7×
PAHCPhibro Animal Health	1.0×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	1.9×
NRIXNurix Therapeutics	3.9×
OMEROmeros	n/m
OGNOrganon	0.6×
AMPHAmphastar Pharmaceuticals	1.5×
Peer median	1.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Zymeworks

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.